Non-Steroidal Anti-inflammatory Drugs Global Market Report 2026
상품코드:1957512
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
비스테로이드성 항염증제(NSAIDs) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 218억 9,000만 달러에서 2026년에는 233억 1,000만 달러에 이르고, CAGR 6.5%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 관절염 및 근골격계 질환의 유병률 증가, 통증 관리 요법에 대한 인식 개선, 노인 인구 증가, 소매 약국 확대, 제제 기술 발전 등을 꼽을 수 있습니다.
비스테로이드성 항염증제(NSAIDs) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 299억 6,000만 달러에 이르고, CAGR은 6.5%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 개인 맞춤형 의료의 도입, 전자 약국 플랫폼의 확대, 새로운 NSAID 제제의 연구 개발 증가, 만성 염증성 질환의 발생률 증가, 통증 모니터링을 위한 디지털 헬스 솔루션의 통합 등을 꼽았습니다. 예측 기간의 주요 동향으로는 개인 맞춤형 통증 관리 솔루션, OTC 항염증제 수요 증가, 속효성 제제 개발, 만성 통증 및 관절염 관리에 대한 집중, 온라인 약국 채널의 확대 등이 있습니다.
근골격계 질환의 유병률 증가는 향후 몇 년 동안 비스테로이드성 항염증제 시장의 성장을 견인할 것으로 예측됩니다. 근골격계 질환(MSDs)은 근육, 뼈, 힘줄, 인대, 관절, 기타 결합조직을 포함한 근골격계에 영향을 미치는 광범위한 병태를 포괄합니다. 비스테로이드성 항염증제(NSAIDs)는 관절염, 골관절염, 류마티스 관절염과 같은 질환에 수반되는 통증과 염증 관리에 중요한 역할을 합니다. 이러한 성장에 기여하는 요인으로는 고령화, 근골격계 질환에 대한 인식과 진단의 향상, 정형외과 수술, 스포츠 관련 부상, 그리고 이러한 질환의 만성적 특성 등이 있습니다. 예를 들어, 2024년 1월 영국 정부 기관 GOV.UK가 발표한 보고서에 따르면, 2023년 16세 이상의 18.4%가 장기 근골격계 질환(MSK)을 앓고 있는 것으로 보고되었으며, 2022년 17.6%에서 증가 추세에 있다고 합니다. 그 결과, 근골격계 질환의 유병률 증가가 비스테로이드성 항염증제(NSAIDs) 시장의 성장을 가속하고 있습니다.
향후 몇 년 동안 만성 통증 증가 추세는 비스테로이드성 항염증제(NSAIDs) 시장 및 관련 통증 관리 솔루션의 성장을 가속할 것으로 예측됩니다. 만성통증이란 관절염, 섬유근육통, 요통, 신경병증성 통증, 기타 근골격계 질환 등으로 인해 발생하는 통증이 3개월 이상 지속되거나 반복되는 통증을 말합니다. 이들 질환은 환자의 삶의 질에 심각한 영향을 미치며, 약물 치료, 물리치료, 지지요법 등 장기적인 관리가 필요한 경우가 많습니다. 만성 통증의 유병률이 증가함에 따라 NSAIDs 및 기타 진통제 등 효과적인 통증 완화 치료에 대한 수요는 지속적으로 증가하고 있습니다. 예를 들어, 2024년 10월 미국 연방정부 연구기관인 국립생물공학정보센터가 발표한 자료에 따르면 성인의 24.3%가 만성통증을 경험하고 있으며, 그 중 8.5%는 일상생활에 지장을 초래하는 심각한 만성통증에 시달리고 있다고 합니다. 그 결과, 만성 통증으로 고통받는 사람들 증가가 통증 관리 요법에 대한 수요를 견인하여 비스테로이드성 항염증제(NSAIDs) 시장 및 관련 제품의 성장을 뒷받침할 것으로 예측됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Non-steroidal anti-inflammatory drugs are medications that help decrease inflammation and reduce fever. They are commonly used to treat conditions such as headaches, sprains, strains, menstrual pain, colds and flu, arthritis, and various chronic pain issues. These drugs help alleviate inflammation, ease pain, and lower elevated body temperature.
The primary routes of administration include oral, topical, and other methods. Topical formulations are typically used to relieve muscle pain, sprains, and strains, as well as to alleviate the discomfort caused by arthritis. These drugs are indicated for conditions such as arthritis, migraines, ophthalmic diseases, and other medical conditions, and are available in hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have created both challenges and opportunities for the non-steroidal anti-inflammatory drugs market by affecting the cost of raw materials, active pharmaceutical ingredients, and imported formulations. The resulting increase in production costs impacts oral and topical segments, particularly in regions like Asia-Pacific and Europe where imports are significant. Hospitals and retail pharmacies face higher procurement costs, while manufacturers are exploring local production and alternative sourcing strategies. Some positive effects include encouraging domestic manufacturing and boosting investment in local supply chains.
The non-steroidal anti-inflammatory drugs market research report is one of a series of new reports from The Business Research Company that provides non-steroidal anti-inflammatory drugs market statistics, including non-steroidal anti-inflammatory drugs industry global market size, regional shares, competitors with a non-steroidal anti-inflammatory drugs market share, detailed non-steroidal anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the non-steroidal anti-inflammatory drugs industry. This non-steroidal anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $21.89 billion in 2025 to $23.31 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of arthritis and musculoskeletal disorders, rising awareness of pain management therapies, growth in geriatric population, expansion of retail pharmacies, advancements in drug formulation technologies.
The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $29.96 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to adoption of personalized medicine, growth of e-pharmacy platforms, increasing r&d in novel nsaid formulations, rising incidence of chronic inflammatory diseases, integration of digital health solutions for pain monitoring. Major trends in the forecast period include personalized pain management solutions, rising demand for otc anti-inflammatory drugs, development of rapid-acting formulations, focus on chronic pain and arthritis management, expansion of online pharmacy channels.
The growing prevalence of musculoskeletal disorders is expected to drive the expansion of the non-steroidal anti-inflammatory drug market in the coming years. Musculoskeletal disorders (MSDs) encompass a wide range of conditions that affect the musculoskeletal system, including muscles, bones, tendons, ligaments, joints, and other connective tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) play a vital role in managing pain and inflammation associated with conditions such as arthritis, osteoarthritis, and rheumatoid arthritis. Contributing factors to this growth include the aging population, greater awareness and diagnosis of musculoskeletal disorders, orthopedic procedures, sports-related injuries, and the chronic nature of these conditions. For example, in January 2024, the UK-based government department GOV.UK reported that in 2023, 18.4% of individuals aged 16 and older reported having a long-term musculoskeletal (MSK) condition, an increase from the 17.6% prevalence recorded in 2022. As a result, the rising prevalence of musculoskeletal disorders is fueling the growth of the non-steroidal anti-inflammatory drugs market.
The increasing prevalence of chronic pain is anticipated to propel the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market and associated pain management solutions in the coming years. Chronic pain refers to persistent or recurrent pain that lasts for three months or more, often resulting from conditions such as arthritis, fibromyalgia, back pain, neuropathic pain, and other musculoskeletal disorders. These conditions have a profound impact on patients' quality of life and frequently require long-term management, which may include medication, physical therapy, and supportive care. As chronic pain becomes more prevalent, the demand for effective pain relief treatments, such as NSAIDs and other analgesic formulations, continues to rise. For example, in October 2024, the National Center for Biotechnology Information, a U.S.-based federal government research agency, reported that 24.3% of adults experienced chronic pain, with 8.5% suffering from high-impact chronic pain that limits daily activities. As a result, the growing number of individuals affected by chronic pain is expected to drive demand for pain management therapies, thereby supporting the expansion of the NSAIDs market and related products.
Leading companies in the non-steroidal anti-inflammatory drugs (NSAIDs) market are focusing on developing innovative solutions, such as combination analgesic-gastroprotective formulations, to address the growing demand for effective pain relief with reduced gastrointestinal risks typically associated with long-term NSAID use. These combination technologies pair an NSAID with a protective agent, allowing for the retention of anti-inflammatory efficacy while minimizing stomach irritation, offering a safer alternative to traditional single-agent NSAIDs. For example, in March 2024, Endo International plc, an Ireland-based pharmaceutical company, introduced ibuprofen-famotidine 800 mg/26.6 mg tablets. This advanced formulation combines the analgesic and anti-inflammatory properties of ibuprofen with the gastroprotective benefits of famotidine. The dual-action tablet is designed to relieve pain while reducing gastrointestinal side effects like ulcers or irritation, which often arise with extended NSAID use, thereby enhancing safety and promoting better patient adherence.
Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Perrigo Company PLC, Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company
North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-steroidal anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-steroidal anti-inflammatory drugs market consists of sales of high-dose aspirin, indomethacin, mefenamic acid, celecoxib, and other types. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Steroidal Anti-inflammatory Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses non-steroidal anti-inflammatory drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-steroidal anti-inflammatory drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-steroidal anti-inflammatory drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Route Of Administration: Oral; Topical; Other Route Of Administration
2) By Disease Indication: Arthritis; Migraine; Ophthalmic Diseases; Other Disease Indications
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Oral: Tablets; Capsules; Liquids Or Solutions
2) By Topical: Gels; Creams; Patches
3) By Other Route Of Administration: Injectable (Intravenous And Intramuscular); Suppositories
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.1.5 Industry 4.0 & Intelligent Manufacturing
4.2. Major Trends
4.2.1 Personalized Pain Management Solutions
4.2.2 Rising Demand For Otc Anti-Inflammatory Drugs
4.2.3 Development Of Rapid-Acting Formulations
4.2.4 Focus On Chronic Pain And Arthritis Management
4.2.5 Expansion Of Online Pharmacy Channels
5. Non-Steroidal Anti-inflammatory Drugs Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Retail Pharmacies
5.4 Online Pharmacies
5.5 Geriatric Care Centers
6. Non-Steroidal Anti-inflammatory Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Non-Steroidal Anti-inflammatory Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Non-Steroidal Anti-inflammatory Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Non-Steroidal Anti-inflammatory Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Non-Steroidal Anti-inflammatory Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Non-Steroidal Anti-inflammatory Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Non-Steroidal Anti-inflammatory Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.1. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Topical, Other Route Of Administration
9.2. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Arthritis, Migraine, Ophthalmic Diseases, Other Disease Indications
9.3. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.4. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Tablets, Capsules, Liquids Or Solutions
9.5. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Topical, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Gels, Creams, Patches
9.6. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Other Route Of Administration, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injectable (Intravenous And Intramuscular), Suppositories
10. Non-Steroidal Anti-inflammatory Drugs Market Regional And Country Analysis
10.1. Global Non-Steroidal Anti-inflammatory Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Non-Steroidal Anti-inflammatory Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Non-Steroidal Anti-inflammatory Drugs Market
12.1. China Non-Steroidal Anti-inflammatory Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Non-Steroidal Anti-inflammatory Drugs Market
13.1. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Non-Steroidal Anti-inflammatory Drugs Market
14.1. Japan Non-Steroidal Anti-inflammatory Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Non-Steroidal Anti-inflammatory Drugs Market
15.1. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Non-Steroidal Anti-inflammatory Drugs Market
16.1. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Non-Steroidal Anti-inflammatory Drugs Market
17.1. South Korea Non-Steroidal Anti-inflammatory Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Non-Steroidal Anti-inflammatory Drugs Market
19.1. South East Asia Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Non-Steroidal Anti-inflammatory Drugs Market
20.1. Western Europe Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Non-Steroidal Anti-inflammatory Drugs Market
21.1. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Non-Steroidal Anti-inflammatory Drugs Market
23.1. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24.1. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25.1. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market
26.1. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Non-Steroidal Anti-inflammatory Drugs Market
27.1. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Non-Steroidal Anti-inflammatory Drugs Market
28.1. North America Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Non-Steroidal Anti-inflammatory Drugs Market
29.1. USA Non-Steroidal Anti-inflammatory Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Non-Steroidal Anti-inflammatory Drugs Market
31.1. South America Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Non-Steroidal Anti-inflammatory Drugs Market
32.1. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Non-Steroidal Anti-inflammatory Drugs Market
33.1. Middle East Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Non-Steroidal Anti-inflammatory Drugs Market
34.1. Africa Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route Of Administration, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Non-Steroidal Anti-inflammatory Drugs Market Regulatory and Investment Landscape
36. Non-Steroidal Anti-inflammatory Drugs Market Competitive Landscape And Company Profiles
